Dr. Kirane is a fellowship-trained, board-certified specialist in complex general surgical oncology. She is an assistant professor in the Department of Surgery, Section of Surgical Oncology, at Stanford University School of Medicine.
Her clinical practice focuses on the diagnosis and treatment of melanoma and other skin cancers. She partners closely with patients and families to provide the most effective treatment approach possible. For each patient, she tailors an evidence-based, personalized care plan that is innovative, comprehensive, and compassionate.
Dr. Kirane has conducted extensive research and been the principal investigator of multiple studies in melanoma and associated malignancies. Her current interests include immune response and novel therapies in melanoma. She has led research into immune therapy for melanoma that is resistant to current standards of care.
The National Institutes of Health, American Society of Clinical Oncology, and others have funded her research. She has co-authored articles on her discoveries in the Journal of Dermatological Treatment, Journal of Surgical Oncology, Journal of Surgical Research, Annals of Surgery, and elsewhere. Topics include advances in non-surgical management of melanoma.
She also co-wrote the chapter on the management of soft tissue sarcoma in the textbook Current Surgical Therapy.
Dr. Kirane has presented updates on the management of melanoma and other cancers to her peers at meetings of the American College of Surgeons, Society of Surgical Oncology, and Society for Immunotherapy in Cancer.
She has earned awards for her achievements in clinical care, research, and scholarship. The Society for Immunotherapy of Cancer, Society of Surgical Oncology, Memorial Sloan Kettering Cancer Center, and other prestigious organizations have honored her work.
Dr. Kirane is a fellow of the American College of Surgeons (FACS) and Society of Surgical Oncology (FSSO). She is a member of the Society for Immunotherapy of Cancer, American Association of Cancer Research, Society for Melanoma Research, Connective Tissue Oncology Society, Association of Academic Surgeons, and Association of Women Surgeons.
She volunteers her time and expertise on behalf of the Melanoma Research Foundation, members of her community in need, STEM programs for girls, and other initiatives. She is also a Pilates instructor.
- General Surgery
- Skin Cancer Surgery
- Immunotherapy, Intratumoral Therapy
Board Certification: American Board of Surgery, General Surgery (2017)
PhD Candidate, University of California at Davis, Immunology (2020)
Board Certification: American Board of Surgery, Surgical Oncology (2018)
Fellowship: Memorial Sloan Kettering Cancer Center Complex Surgical Oncology (2016) NY
Residency: University of Texas Southwestern Medical Center (2014) TX
Medical Education: University of Texas Southwestern Medical School Registrar (2006) TX
MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients
Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
- Design, Synthesis, Anticancer and Antimicrobial Studies of 2-Phenylthiazolidin-4-one Glycinamide Conjugates CHEMISTRYSELECT 2023; 8 (42)
Detection of Circulating Tumor DNA Predicts Recurrence in Soft Tissue Sarcomas
SPRINGER. 2023: S16
View details for Web of Science ID 001046841200028
The Impact of Mesenchymal Transition and Macrophage Phenotype in Immunotherapy-Resistant Melanoma
SPRINGER. 2023: S236
View details for Web of Science ID 001046841200519
- Intralesional Interleukin-2 Augmentation Therapy in Treatment-Refractory Melanoma. Dermatologic therapy 2022: e15853
The Role of AXL Tyrosine Kinase in the Melanoma Immune Microenvironment
SPRINGER. 2022: 465
View details for Web of Science ID 000789811800310
Neoadjuvant Intralesional Therapy for High Risk Stage II Melanoma
SPRINGER. 2022: 534
View details for Web of Science ID 000789811800468